Cagrilintide

Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is developed by Novo Nordisk and studied both as a monotherapy and in combination with semaglutide (CagriSema).

Mechanism

• Amylin receptor agonism. Slows gastric emptying, reduces appetite via central pathways, modulates postprandial glucagon.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• Clinical trial dosing. Weekly subcutaneous injection, typically titrated over multiple weeks. Studied as monotherapy and in CagriSema combination trials.
• Status. Not FDA-approved as monotherapy at publication. CagriSema (with semaglutide) in Phase 3.

Evidence at a glance

• Human data. Phase 2 trials show meaningful weight reduction and additive effect when paired with semaglutide.
• Known side effects. GI-related, similar profile to the GLP-1 class.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How It Works page.

Primary-literature list for this guide available on request via contact.